TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03745898

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen
Description: Active nocturnal oxygen concentrator

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Room Air
Description: Sham nocturnal oxygen concentrator (room air)
Study: NCT02807883

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: Participants receive Blinatumomab as continuous intravenous infusion at a dose of 28 µg/24 hours over 4 weeks followed by a treatment-free period of 2 weeks, defined as one 6-week treatment cycle. In the first induction cycle, the initial dose of Blinatumomab is 9 µg/day for the first 7 days of treatment which then will be escalated (dose step) to 28 µg/day starting on day 8 (week 2) through day 29 (week 4). For all subsequent cycles, 28 µg/day is the dose for all 4 weeks of continuous treatment. Participants receive 4 cycles of blinatumomab at 3, 6, 9, and 12 months following hematopoietic cell transplantation (HCT).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hematopoietic Cell Transplantation
Description: Hematopoietic progenitor cell infusion
Study: NCT02142153

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F901318
Description: Comparison of adverse events, clinically significant safety laboratory abnormalities and ECG abnormalities.~Pharmacokinetic profile

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F901318
Description: Comparison of adverse events, clinically significant safety laboratory abnormalities and ECG abnormalities.~Pharmacokinetic profile

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F901318
Description: Comparison of adverse events, clinically significant safety laboratory abnormalities and ECG abnormalities.~Pharmacokinetic profile

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F901318
Description: Comparison of adverse events, clinically significant safety laboratory abnormalities and ECG abnormalities.~Pharmacokinetic profile

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F901318
Description: Comparison of adverse events, clinically significant safety laboratory abnormalities and ECG abnormalities.~Pharmacokinetic profile

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Comparison of adverse events and clinically sign significant safety lab and ECG abnormalities

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Comparison of adverse events and clinically sign significant safety lab and ECG abnormalities

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Comparison of adverse events and clinically sign significant safety lab and ECG abnormalities

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Comparison of adverse events and clinically sign significant safety lab and ECG abnormalities

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Comparison of adverse events and clinically sign significant safety lab and ECG abnormalities
Study: NCT00022737

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: asparaginase
Description: Given IM

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IT and IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daunorubicin hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ifosfamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib mesylate
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV or orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mercaptopurine tablet
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Given IT, IV, and orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegaspargase
Description: Given IM

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic bone marrow transplantation
Description: Undergo allogeneic bone marrow, peripheral blood stem cell, or umbilical cord blood transplantation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Description: Undergo allogeneic bone marrow, peripheral blood stem cell, or umbilical cord blood transplantation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: umbilical cord blood transplantation
Description: Undergo allogeneic bone marrow, peripheral blood stem cell, or umbilical cord blood transplantation

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Undergo radiation therapy
Study: NCT03439267

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Coronary Artery Calcium Screening and Statin Treatment
Description: Will undergo coronary artery calcium screening and will receive statin treatment based on the cardiovascular risk algorithm.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Treatment
Description: Patients will be managed following the AHA/ACC guidelines for statin initiation and follow-up.
Study: NCT04744753

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium Ionophore A23187
Description: Calcium Ionophore A23187 is used in laboratories to increase intracellular Ca2+ levels in intact cells. It also uncouples oxidative phosphorylation, the process cells use to synthesize Adenosine triphosphate which they use for energy. In addition, A23187 inhibits mitochondrial ATPase activity. A23187 also induces apoptosis in some cells (e.g. mouse lymphoma cell line, or S49, and Jurkat cells) and prevents it in others (e.g. cells dependent on interleukin 3 that have had the factor withdrawn).~In IVF field, Ca Ionophore can be used in case of low fertilization rate after ICSI procedure, particularly with Globozoospermia (Round Head sperm syndrome), Ca Ionophore will replace absence of sperm acrosom, and plays role in oocyte activation after ICSI. Recommended use is 0.5 microgram/ml twice for 10 min interrupted with fresh media with 30 min incubation, followed with regular injected eggs culture for IVF.
Study: NCT04050085

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TLR9 Agonist SD-101
Description: Given intratumorally
Study: NCT03953599

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19-STAR-T cells
Description: CD19-STAR-T cells are prepared via lentiviral infection. 5 days prior to infusion of STAR-T cells, subjects receive fludarabine at dose 30mg/m2/day and cyclophosphamide treatment at dose 250mg/m2 for 3 days and take a rest for 2 days before infusion.
Study: NCT03363139

Intervention type: DRUG
Intervention: Tirosin Kinase Inhibitors
Description: Patients that received Tyrosin Kinase inhibitors and progressed
Study: NCT04796077

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pop-Up Book
Description: Patients spent 5-10 minutes reading an illustrated pop-up book that promoted active learning about the process of general anesthesia induction.
Study: NCT04531020

Intervention type: DIAGNOSTIC_TEST
Intervention: PAED measurement
Description: The incidence of emergence delirium, defined as PAED score above 10 points minimally in one of the PAED score measurements. PAED score will be measured in 0., 5., 10., 15., and 20. minute after PACU admission.
Study: NCT02908763

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa
Description: peginterferon alfa-2a 180 micrograms/week or peginterferon alfa-2b 80 micrograms/week, for at most 96 weeks.
Study: NCT03462004

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HPIV3/ΔHNF/EbovZ GP vaccine
Description: Administered intranasally

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HPIV3/ΔHNF/EbovZ GP vaccine
Description: Administered intranasally

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered intranasally

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered intranasally
Study: NCT05570604

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sweep Seeker
Description: The person is asked to clear the rows of blocks presented on the screen, either by moving them into horizontal or vertical blocks that have identical color. The goal is to refine and increase the response of primary visual cortex neurons and to enable the person to increase speed and accuracy of visual processing (executive function) and visual memory.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bird Safari
Description: The user is first presented with a target bird. Subsequently, a group of birds is presented in the peripheral vision and then disappears when the trial begins. The user selects the section of the screen where the target bird appeared. The presentation speed adapts with user performance (i.e. better performance = faster presentation). The goal is to improve speed and accuracy of object identification in peripheral vision and improve visual precision important for improving memory.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Jewel Diver
Description: The person is first presented objects (jewels) on the screen. The objects are then covered with occluders (bubbles) and then identical distracters are presented. The objects move around in screen and when the movement stops, the user chooses the occluders that cover the jewels. The number of jewels adapts to performance (more jewels = better performance). The goal is to improve divided visual attention, sustained visual attention, visual working memory, and visual precision.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Master Gardener
Description: The person is presented a series of target stimuli and distracters which are presented at one time and then disappear. The locations of the stimuli are marked by icons, and the user chooses the icons where the target stimuli were once located. The goal is to increase speed and accuracy as well as the ability to extract information accurately.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Road Tour
Description: The person is presented with a target vehicle briefly in both the center of the screen and in one of eight locations in the periphery. Two vehicles are then presented briefly in the center of the screen, one of which is the target vehicle. The user must identify the location of the target vehicle in the periphery as well as identify which was the target vehicle that appeared in the center. The goal of this activity is to improve divided attention and ability to extract information and discard irrelevant information from peripheral vision.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Computerized Crossword Puzzles
Description: The program offers a pre-determined set of computerized crossword puzzles. The site has over 100,000 puzzles and can be accessed easily via the web and are free to users. The computerized crossword puzzles do not provide for progressive challenges of increasing speed, visual field size, number of distractors or degree of difficulty of targeted stimulus differentiation.
Study: NCT02661191

Intervention type: DRUG
Group type: OTHER
Intervention: oral cholecalciferol
Description: Inhaled corticosteroids and long-acting beta-agonists, salbutamol
Study: NCT00778349

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin solution 100 mg/mL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin solution 100 mg/mL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin solution 100 mg/mL
Study: NCT03131687

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tirzepatide
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tirzepatide
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tirzepatide
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tirzepatide
Description: Administered SC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dulaglutide
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered SC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study: NCT05677958

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 125 mL Fortimel/Nutridrink Compact Protein
Description: 125 mL Fortimel/Nutridrink Compact Protein®\* two servings per day (300 kcal, 18 g protein per serving).
Study: NCT03945318

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BION-1301 Single Dose
Description: A solution for IV infusion administered as a single dose.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Single Dose
Description: A solution by IV infusion administered as a single dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BION-1301 Multiple Doses
Description: A solution for IV infusion or SC injections (Part 3 only) administered as multiple doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BION-1301 Multiple Doses
Description: A solution for IV infusion or SC injections (Part 3 only) administered as multiple doses.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Multiple Doses
Description: A solution by IV infusion administered as multiple doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BION-1301 Single Dose
Description: SC injection administration as a single dose using vials or pre-filled syringes (PFS) (Part 4 only).
Study: NCT01904032

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: 50,000 international units (IUs) weekly Vitamin D3

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3 comparator
Description: 5,000 international units (IUs) of a weekly Vitamin D3 comparator
Study: NCT04555707

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast 30mg
Description: 30mg PO BID started within 10 days of baseline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: calcipotriene and betamethasone dipropionate
Description: 1 application daily starting at baseline and continuing for 4 weeks; those achieving clear or almost clear PGA at week 4 will continue application twice weekly on Monday and Thursday in combination with Otezla. Enstilar application is discontinued at week 16 and study participation continues until week 20.
Study: NCT03367234

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual Therapy Sessions
Description: One-on-one sessions with a counselor

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Individual Therapy Sessions
Description: One-on-one sessions with a counselor

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Description: Cognitive Behavioral Therapy techniques delivered by a behavioral health consultant (BHC)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medication-Assisted Treatment
Description: Buprenorphine or Extended-Release Naltrexone

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Medication-Assisted Treatment
Description: Buprenorphine or Extended-Release Naltrexone

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Recovery Specialist Support
Description: Individual and/or group sessions with a certified peer recovery specialist

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Peer Recovery Specialist Support
Description: Individual and/or group sessions with a certified peer recovery specialist

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group Therapy Sessions
Description: Group therapy sessions

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychiatric Consultation
Description: Access to psychiatric consultation

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychiatric Consultation
Description: Access to psychiatric consultation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency Management
Description: Rewards for engagement in specified recovery behaviors
Study: NCT00098670

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: alemtuzumab
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: Given IV
Study: NCT01187277

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: conventional therapy
Description: conventional therapy means: 50 min individual physiotherapy and 60 min individual occupational therapy per work day (5x per week)for four consecutive weeks

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: conventional plus robotic gait assisted therapy
Description: individual physiotherapy +individual occupational therapy+ robotic gait assisted therapy
Study: NCT03655457

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: group 1 Poractant alfa
Description: Comparison of lung usg scores in infants treated with Poractant alfa and Beractant: 0 indicates A-pattern (defined by the presence of the only A-lines); 1, B-pattern (defined as the presence of ≥3 well-spaced B-lines); 2, severe B-pattern (defined as the presence of crowded and coalescent B-lines with or without consolidations limited to the subpleural space); and 3, extended consolidations.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: group 2 beractant
Description: lComparison of lung usg scores in infants treated with Poractant alfa and Beractant: 0 indicates A-pattern (defined by the presence of the only A-lines); 1, B-pattern (defined as the presence of ≥3 well-spaced B-lines); 2, severe B-pattern (defined as the presence of crowded and coalescent B-lines with or without consolidations limited to the subpleural space); and 3, extended consolidations.
Study: NCT02397382

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab
Description: Guselkumab will be administered as a single dose of 200 milligram (mg) by subcutaneous injection (2\*100 mg) on Day 8.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Midazolam will be administered orally as probe cocktail containing 0.03 mg per kilogram (kg) once on Day 1, 15 and 36.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin
Description: Warfarin will be administered orally as probe cocktail containing 10 mg once on Day 1, 15 and 36.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: Omeprazole will be administered orally as probe cocktail containing 20 mg once on Day 1, 15 and 36.
Study: NCT03762681

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7239958
Description: Solution for injection, subcutaneous use (SC).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7239958
Description: Solution for injection, subcutaneous use (SC).
Study: NCT02397382

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextromethorphan
Description: Dextromethorphan will be administered orally as probe cocktail containing 30 mg once on Day 1, 15 and 36.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: Caffeine will be administered orally as probe cocktail containing 100 mg once on Day 1, 15 and 36.
Study: NCT02038387

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: normocaloric low cholesterol diet
Study: NCT02847286

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapivirine Ring-004
Description: Treatment A: Dapivirine Ring-004 for 28 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapivirine Ring-004 for 28 days along with clotrimazole
Description: Treatment B: Dapivirine Ring-004 for 28 days along with clotrimazole, 5 g per day for 7 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clotrimazole
Description: Treatment C: Clotrimazole, 5 g per day for 7 days
Study: NCT05812742

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early intervention programme
Description: For more information, please go to the original registration of the RCT-study (NCT02337101) or the published article (PMID: 31891145).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced usual care
Description: For more information, please go to the original registration of the RCT-study (NCT02337101) or the published article (PMID: 31891145).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced usual care
Description: For more information, please go to the original registration of the RCT-study (NCT02337101) or the published article (PMID: 31891145).
Study: NCT03899831

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Function-Based Elopement Treatment (FBET)
Description: The Function-Based Elopement Treatment (FBET) includes 12 appointments over 16 weeks. FBET focuses on parent-training, with the parent implementing procedures with therapist support. The goals of FBET are:~* to create a safer environment~* teach adaptive skills to replace elopement~* arrange the environment and rewards to reduce elopement~* and teach caregivers how to respond if elopement occurs Psychoeducation is emphasized, including discussions of elopement as a learned behavior, reinforcement, functions of elopement, extinction, and descriptions of treatment components. The FBET manual includes scripted text, examples, caregiver completed activities, and checks for understanding.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Parent Education Program (PEP)
Description: The Parent Education Program (PEP) will include 12 appointments over 16 weeks, focused on general education about autism spectrum disorder and resources about elopement prevention. PEP will be administered by a Board Certified Behavior Analyst (BCBA). Participants randomized to the PEP study arm can receive the FBET intervention after completing the 16 week study period.